Parabilis Medicines raised $305 million in a Series F financing to advance its corkscrew‑shaped peptide platform against intracellular and previously 'undruggable' protein targets. The round, led by major crossover and venture investors, will support late‑stage development of zolucatetide and other pipeline candidates and fund work toward potential registrational paths. Company leadership signaled openness to a future IPO as financing de‑risks lead programs. Parabilis said the cash infusion will expand clinical testing and combination strategies, positioning the company to accelerate development timelines for oncology indications where intracellular targeting has been historically intractable.